QIAGEN(QGEN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - QIAGEN exceeded its fourth quarter Outlook with net sales of $540 million, growing 1% at constant exchange rates (CER) compared to flat sales development expected against Q4 2024 [5][6] - For the full year 2025, net sales reached $2.09 billion, up 5% at CER, at the upper end of the Outlook of about 4%-5% growth [6][12] - Adjusted diluted EPS for Q4 was $0.62 at CER, exceeding the Outlook of approximately $0.60, while for the full year, it increased to $2.40 at CER, above the initial Outlook [6][12] Business Line Data and Key Metrics Changes - Sample Technologies achieved 5% growth at CER in Q4 and 2% for the full year, driven by demand for automated consumables [7][16] - QuantiFERON sales grew 5% at CER in Q4 and 10% for the full year, supported by ongoing conversion in the latent TB testing market [8][16] - QIAstat-Dx grew 15% at CER in Q4 and 24% for the full year, benefiting from menu expansion and a growing install base [8][16] - QIAcuity saw double-digit growth in consumables, with over 3,200 instruments installed globally [8][16] Market Data and Key Metrics Changes - Sales in the Europe, Middle East, and Africa region increased by 5% at CER in Q4, with Belgium, the Netherlands, Spain, and the UK as top performers [17] - In the Americas, sales declined by 1% at CER, with the U.S. being flat, partly due to the government shutdown [18] - Sales in the Asia-Pacific-Japan region were flat, with a low-teens decline in China, which represents only about 4% of total sales [18] Company Strategy and Development Direction - QIAGEN aims for at least $2 billion in combined sales from its growth pillars by 2028, reflecting continued demand and long-term investment strategies [7][10] - The company is focused on disciplined execution, cost management, and investment in growth pillars, including the recent acquisition of Parse Biosciences to enhance its Sample Technologies portfolio [10][22] - New product launches and expansions in automation are expected to drive growth, with a target of $720 million in Sample Technologies sales for 2026 [36][70] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a cautious funding and capital spending environment but expressed confidence in gradual improvement throughout 2026 [35][69] - The company anticipates a sales growth of at least 5% for 2026 and adjusted EPS of at least $2.50 at CER, despite headwinds from discontinued products and competitive pressures [29][33] - Management remains focused on operational efficiency and margin improvement, targeting an adjusted operating income margin of at least 31% by 2028 [19][33] Other Important Information - QIAGEN returned over $1.1 billion to shareholders since 2024 and introduced an annual dividend payment [10][20] - The company completed the acquisition of Parse Biosciences, enhancing its capabilities in single-cell analysis [22][24] - A new supervisory board member, Mark Stevenson, was welcomed, bringing operational and global life sciences experience [10][11] Q&A Session Summary Question: Insights on new product launches and growth targets - Management indicated that new product launches are expected to open new markets and contribute to growth, with confidence in achieving the $250 million target for digital PCR by 2028 despite previous delays [40][42] Question: Comments on potential acquisition rumors - Management stated that while the market is undergoing consolidation, QIAGEN is focused on executing its solid growth plan and does not comment on rumors [48] Question: Update on CEO succession search - The search for a new CEO is ongoing, with both internal and external candidates being considered, and management is committed to finding the best fit for the role [50] Question: Clarification on margin expansion and operating leverage - Management expects significant margin improvement in 2026, driven by gross margin enhancements and operational efficiency programs, despite headwinds from acquisitions and tariffs [53][55] Question: Outlook for China and exposure to VBP - Management confirmed limited exposure to China, with expectations of low single-digit to negative growth due to market conditions, and stated that VBP has been a factor for several years [58][60] Question: Expectations for QIAstat-Dx placements and growth - Management expressed confidence in achieving the target of over $160 million for QIAstat-Dx in 2026, with a focus on executing product launches and market penetration [62][74]